ICICI Bank has announced its schedule for upcoming investor meetings in September 2025. The bank will participate in the J.P. Morgan 10th Annual India Conference on September 22, 2025, and the Investec USA India CXO Virtual Conference on September 23, 2025. Bank representatives will be referring to publicly available documents during these discussions.

Upcoming Investor Interactions

ICICI Bank is scheduled to engage with investors at two prominent events in September 2025. These interactions will provide an opportunity for the bank to share insights and updates with the investment community. The bank intends to leverage publicly accessible documentation during these discussions.

Conference Participation

The confirmed events are:

J.P. Morgan 10th Annual India Conference: Scheduled for September 22, 2025, this is an in-person group event.

Investec USA India CXO Virtual Conference: Scheduled for September 23, 2025, this is a virtual group event.

Source: BSE

Fortmax Chemicals India Private Limited (FCIPL) is no longer a step-down subsidiary of Thermax. This change occurred following the allotment of equity shares to Oswaldo Cruz Química Indústria e Comércio Ltda. (OCQ). FCIPL has allotted 44,10,000 equity shares at par to OCQ, representing 49% of FCIPL’s equity share capital.

Fortmax Chemicals Restructuring

Thermax has announced a change in the subsidiary structure of Fortmax Chemicals India Private Limited (FCIPL). A resolution passed on September 16, 2025, approved the allotment of equity shares in FCIPL to Oswaldo Cruz Química Indústria e Comércio Ltda. (OCQ), resulting in FCIPL no longer being a step-down subsidiary.

Details of Equity Allotment

FCIPL has allotted 44,10,000 equity shares with a face value of ₹10 each to OCQ. This allotment represents 49% of FCIPL’s total equity share capital.

Revised Shareholding Pattern

Following the equity allotment, the shareholding pattern of FCIPL has changed. Thermax Chemical Solutions Private Limited now holds 51%, while Oswaldo Cruz Química Indústria e Comércio Ltda. (OCQ) holds 49% of the shares.

Source: BSE

REC Limited announces the appointment of Statutory Auditors for the financial year 2025-26. M/s. Kailash Chand Jain & Co. and M/s. SCV & Co LLP, Chartered Accountants, will serve as the Statutory Auditors. Both firms were previously appointed for the prior two financial years.

Statutory Auditor Appointments

REC Limited has formally appointed its Statutory Auditors for the financial year 2025-26. The appointments, effective as of September 10, 2025, involve two firms of Chartered Accountants.

Details of Appointed Firms

The firms appointed as Statutory Auditors are:

• M/s. Kailash Chand Jain & Co., Chartered Accountants, located at 819, Laxmi Deep Building, Laxmi Nagar, District Center, New Delhi – 110092.
• M/s. SCV & Co LLP, Chartered Accountants, located at B-41, Panchsheel Enclave, New Delhi – 110017.

About M/s. Kailash Chand Jain & Co.

M/s. Kailash Chand Jain & Co. was founded in 1990 and has offices in Mumbai (Head Office), Delhi, Indore, Bhopal, Kolkata, and Raipur. The firm has a total of 14 partners, 3 of whom are DISA-qualified. They offer a range of services including audit, assurance, tax, and consulting.

About M/s. SCV & Co. LLP

SCV & Co. LLP is a professional services firm having five offices (Delhi, Noida, Ludhiana, Mumbai and Bengaluru). It comprises over three hundred and fifty committed team members and Fourteen Partners. The firm provides services like Assurance, Risk Advisory, Tax Advisory, Corporate Advisory and Outsourcing.

Source: BSE

Bikaji Foods International Limited announced the appointment of M/s S.K. Joshi & Associates and M/s V. M. & Associates as Joint Secretarial Auditors during its Annual General Meeting held on September 16, 2025. Both firms will serve for a term of five consecutive years, effective from April 1, 2025, to March 31, 2030.

Joint Secretarial Auditors Appointed

During its Annual General Meeting on September 16, 2025, Bikaji Foods International Limited approved the appointment of two firms to serve as Joint Secretarial Auditors.

Details of the Appointments

The appointed firms are M/s S.K. Joshi & Associates and M/s V. M. & Associates. Both appointments are for a term of five consecutive years, spanning from April 1, 2025, to March 31, 2030.

Profile of M/s S.K. Joshi & Associates

M/s S.K. Joshi & Associates, established in 2006, focuses on corporate law and listing agreements for IPOs, rights issues, and other offerings. The firm also handles mergers and takeovers.

Profile of M/s V. M. & Associates

Established in 1995, M/s V. M. & Associates provides services in secretarial audits, due diligence, IPOs, and regulatory compliance. The firm’s principal office is located in Jaipur, Rajasthan.

Source: BSE

Bank of Baroda has announced the extension of tenure for Shri Sanjay Vinayak Mudaliar as Executive Director. The extension is effective from December 31, 2025, until his superannuation on July 31, 2028, or until further orders, whichever comes earlier. This decision allows for continued leadership and expertise within the bank’s executive team.

Executive Director Tenure Extended

Shri Sanjay Vinayak Mudaliar’s term as Executive Director at Bank of Baroda has been extended beyond his current term ending on December 31, 2025. This extension ensures continuity in the bank’s leadership.

Extension Details

The tenure is extended up to July 31, 2028, which marks his superannuation date. However, the extension will be valid until July 31, 2028, or until any further orders are issued, whichever occurs earlier. This decision reinforces the bank’s commitment to stable and experienced management.

Source: BSE

Balrampur Chini Mills has been assigned a ‘Crisil ESG 62’ rating by Crisil ESG Ratings & Analytics Limited, placing the company under the Strong category. This rating reflects the company’s performance based on publicly available data for FY 2024-25. The company received the rating report on September 15, 2025. Further information can be found on Crisil’s website and the company’s website.

ESG Rating Announcement

Balrampur Chini Mills announced that it has received an ESG rating from Crisil ESG Ratings & Analytics Limited. The rating, a ‘Crisil ESG 62’, places the company in the Strong category, indicating a robust environmental, social, and governance performance.

Rating Details and Scope

The ‘Crisil ESG 62’ rating was voluntarily assigned to Balrampur Chini Mills. The assessment was based on publicly accessible data for the fiscal year 2024-25, suggesting the rating reflects the company’s recent sustainability practices and disclosures. The company received official confirmation of the rating on September 15, 2025.

Accessing Further Information

Detailed information regarding the ESG rating and the methodology used by Crisil is available on the Crisil website, as well as on the Balrampur Chini Mills website.

Source: BSE

Bank of Baroda has announced the extension of Shri Lalit Tyagi’s tenure as Executive Director. The extension, effective from September 15, 2025, grants him an additional three years in his role. This decision follows the powers conferred under relevant sections of the Banking Companies Act. The extended term will last until November 20, 2025, or until further notice, whichever occurs sooner.

Executive Director Tenure Extension

Shri Lalit Tyagi will continue to serve as Executive Director at Bank of Baroda. The extension was formally approved on September 15, 2025, and provides an additional three years in his current position.

Details of the Extension

The decision to extend Shri Lalit Tyagi’s tenure is based on the authority granted by the Banking Companies (Acquisition and Transfer of Undertakings) Act, 1970. His extended term will continue until November 20, 2025, or until any further orders are issued, with the earlier date taking precedence.

Source: BSE

HCLTech has launched HCL Unica+ in India, an AI-first MarTech platform designed for the Intelligence Economy. Unveiled at the ET MarTech+ Summit & Awards 2025, the platform aims to help Indian businesses deliver hyper-personalized, data-driven marketing at scale. It manages 500 million customer accounts across 1.4 billion potential touchpoints in 28 languages.

HCLTech’s New AI Platform

HCLTech through HCLSoftware has announced the launch of HCL Unica+, an AI-first MarTech platform in India. The announcement was made on September 16, 2025. This platform is geared towards enabling Indian businesses to scale up personalized and data-driven marketing initiatives.

Addressing Market Needs

HCL Unica+ is designed to address the unique challenges of India’s diverse and multi-lingual landscape. It aims to facilitate brands in connecting effectively with a digital-native population that seeks relevance in their interactions.

Executive Insights

Rajesh lyer, Executive Vice President & Portfolio General Manager, Business & Industry Solutions, HCLSoftware, stated that HCL Unica+ will help marketers leverage deep customer insight to deliver meaningful moments.

Platform Capabilities

The platform currently manages 500 million customer accounts across 1.4 billion potential touchpoints, supporting communications in 28 languages. This showcases its capability to handle demanding and large-scale challenges within the Indian market.

MarTech Industry Growth

As India’s MarTech industry anticipates growth to nearly $94 billion by 2030, HCL Unica+ is positioned to enable enterprises to capitalize on the future of marketing. According to Rajiv Shesh, Chief Revenue Officer, HCLSoftware, HCL Unica+ will redefine customer experience by helping marketers understand evolving customer needs to build real trust.

Industry Validation

Sidhant Khanna, SVP, IndusInd Bank, noted that with AI-powered insights, they can anticipate customer needs and deliver hyper-personalized experiences that build trust and growth.

Partnership and Vision

Harish Padmanabhan, Director – Global Partnerships, Xerago, described HCL Unica+ as an AI-first, data-driven, integrated marketing automation platform. He said Xerago is proud to partner with HCLSoftware in delivering this platform, driving rapid ROI and future-ready agility for leading brands.

Source: BSE

Bajaj Holdings & Investment has amended its ‘Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information’. The board approved these changes at a meeting held on September 16, 2025. The amended code ensures transparency and proper handling of sensitive information within the company. This aligns with regulatory requirements for fair disclosures.

Amendment to Disclosure Code

Bajaj Holdings & Investment has announced an amendment to its ‘Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information’ (the ‘Code’). The announcement was made on September 16, 2025.

Details of the Amendment

The amendment follows the guidelines for fair disclosure. The amended code has been posted on the company’s website for stakeholders.

Key Points of the Amended Code:

Legitimate Purposes: The term includes sharing UPSI in the ordinary course of business with various parties, provided it doesn’t evade prohibitions.

UPSI Definition: As defined under relevant regulations and the Company’s Code of Conduct.

Prompt Disclosure: Ensuring prompt public disclosure of UPSI impacting price discovery.

Uniform Dissemination: Ensuring uniform dissemination of UPSI to avoid selective disclosure.

CIRO Role: The Compliance Officer acts as the Chief Investor Relations Officer (CIRO).

Handling Queries: Ensuring appropriate and fair responses to news reports and market rumors.

Analyst Information: Ensuring shared information with analysts isn’t UPSI.

Record Keeping: Maintaining records of analyst interactions and investor conferences.

Need-to-Know Basis: Handling all UPSI on a need-to-know basis.

Insider Definition: Persons receiving UPSI for a “legitimate purpose” are considered “insiders.”

Digital Database: A structured digital database is maintained with details of those with whom UPSI is shared.

Policy for Legitimate Purposes

Principles: Including authority to seek/provide information, disclosed purpose, necessity, timeliness, conditions, regulatory compliance, consistency, and not being for trading.

Deemed Legitimate: Sharing financial data with auditors, complying with investigations, and adhering to court orders.

Compliance: Aligning with laws, regulations, and contractual obligations.

Process for Sharing UPSI

Satisfying information is UPSI, identifying recipients, notifying recipients of confidentiality, and choosing the appropriate mode of sharing.

Database Maintenance

Maintaining structured databases with necessary identifiers and controls to prevent tampering.

Policy Review

The Policy shall be reviewed periodically for regulatory requirements. Provisions of law shall override this policy.

Source: BSE

Dr. Reddy’s Laboratories has launched Tegoprazan, a novel patented molecule, in India for acid-related gastrointestinal diseases under the brand name PCAB®. This launch follows an exclusive partnership with HK inno.N Corporation. Tegoprazan, a next-generation potassium-competitive acid blocker, addresses a critical need in acid peptic disease management. It has already been approved in 21 countries and has completed Phase-III trials in the United States.

Tegoprazan Launch in India

Dr. Reddy’s Laboratories has announced the launch of its novel molecule, Tegoprazan, in India, indicated for acid-related gastrointestinal diseases. The drug will be marketed under the brand name PCAB®.

About Tegoprazan

Tegoprazan is a next-generation potassium-competitive acid blocker used to treat acid peptic diseases (APD) such as Erosive Gastroesophageal Reflux Disease (GERD), Non-Erosive Gastroesophageal Reflux Disease (NERD), and Gastric Ulcer. It offers fast action and prolonged gastric pH control, benefiting APD management.

Impact on the Market

With approximately 38% of the Indian population affected by APD, Tegoprazan’s launch addresses a significant need for effective management strategies. Clinical trials have shown promising results, including 99% endoscopic healing in GERD patients within 8 weeks in a multinational trial across India, South Africa, and Russia.

Executive Commentary

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets) at Dr. Reddy’s, stated that the launch reinforces the company’s commitment to innovation in gastrointestinal disease treatment. Dal-Won Kwak, Chief Executive Officer at HK inno.N Corporation, expressed honor in introducing Tegoprazan to the Indian market, hoping it will become a leading therapy in its class.

Global Presence

Tegoprazan has already been approved in 21 countries, including South Korea and China, and is currently under registration in several other countries. It has also successfully completed Phase-III trials in the United States, indicating a broad potential market reach.

Source: BSE